Randomized phase II study for treatment optimization of the treatment of prostate cancer hormonrefraktaren with docetaxel + prednisone versus docetaxel + prednisone + low-dose cyclophosphamide [Randomisierte Phase II Studie zur Therapieoptimierung der Behandlung des hormonrefraktaren Prostatakarzinoms mit Docetaxel + Prednison versus Docetaxel + Prednison + low dose Cyclophosphamid]

Trial Profile

Randomized phase II study for treatment optimization of the treatment of prostate cancer hormonrefraktaren with docetaxel + prednisone versus docetaxel + prednisone + low-dose cyclophosphamide [Randomisierte Phase II Studie zur Therapieoptimierung der Behandlung des hormonrefraktaren Prostatakarzinoms mit Docetaxel + Prednison versus Docetaxel + Prednison + low dose Cyclophosphamid]

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2013

At a glance

  • Drugs Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Prednisone (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top